Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
17.04
+0.25 (1.52%)
At close: May 12, 2025, 4:00 PM
17.04
0.00 (0.00%)
After-hours: May 12, 2025, 4:39 PM EDT
Castle Biosciences Revenue
Castle Biosciences had revenue of $87.99M in the quarter ending March 31, 2025, with 20.57% growth. This brings the company's revenue in the last twelve months to $347.08M, up 38.43% year-over-year. In the year 2024, Castle Biosciences had annual revenue of $332.07M with 51.09% growth.
Revenue (ttm)
$347.08M
Revenue Growth
+38.43%
P/S Ratio
1.36
Revenue / Employee
$456,088
Employees
761
Market Cap
491.98M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CSTL News
- 3 days ago - Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result - GlobeNewsWire
- 5 days ago - Castle Biosciences Celebrates Skin Cancer Awareness Month - GlobeNewsWire
- 6 days ago - Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Castle Biosciences Reports First Quarter 2025 Results - GlobeNewsWire
- 7 days ago - Castle Biosciences to Acquire Previse - GlobeNewsWire
- 10 days ago - New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer - GlobeNewsWire
- 12 days ago - New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity - GlobeNewsWire
- 14 days ago - DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma - GlobeNewsWire